AbbVie Inc (ABBV)vsAuna S.A. (AUNA)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
AUNA
Auna S.A.
$5.17
-0.10%
HEALTHCARE · Cap: $382.87M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1280% more annual revenue ($64.39B vs $4.67B). ABBV leads profitability with a 9.8% profit margin vs 0.3%. ABBV trades at a lower P/E of 72.0x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AUNA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for AUNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.9% — below average capital efficiency
0.3% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : AUNA
The strongest argument for AUNA centers on Price/Book. Revenue growth of 13.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. A P/E of 86.2x leaves little room for execution misses. Debt-to-equity of 2.01 is elevated, increasing financial risk.
Key Dynamics to Monitor
AUNA carries more volatility with a beta of 0.62 — expect wider price swings.
AUNA is growing revenue faster at 13.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 49/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a leading telecommunications and digital services provider in Latin America, renowned for its comprehensive suite of integrated solutions that enhance connectivity for both residential and business clients. The company delivers a diverse range of high-speed internet, television, and mobile services, underscoring its commitment to innovation and exceptional customer experience. With a strong infrastructure and strategic market positioning, Auna is poised to capitalize on the growing demand for advanced telecommunications services, making it an attractive investment opportunity for institutional investors seeking to engage in the expanding digital economy in the region.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?